BMP10 Antibody

What is BMP10 and why is it significant for cardiovascular research?

BMP10 is a member of the TGF-β receptor family that plays essential roles in cardiogenesis and cardiovascular function. It is highly expressed in the developing heart, and BMP10 deletion in mice results in embryonic lethality due to impaired cardiac development . In adults, BMP10 expression is primarily restricted to the right atrium, but ventricular hypertrophy is accompanied by increased BMP10 expression in hypertension models . Recent research has identified BMP10 as a novel biomarker associated with the risk of ischemic stroke and other outcomes in patients with atrial fibrillation (AF) . Its signaling activity is critical for maintaining cardiac function, and it works with BMP9 in regulating endothelial function .

What types of BMP10 antibodies are available for research?

Based on current literature and commercial availability, several types of BMP10 antibodies are used in research:

Different antibodies target either the prodomain or the mature domain of BMP10, making them useful for distinct research purposes .

How do I select the appropriate BMP10 antibody for my experiment?

Selection should be based on your specific research application:

• For detecting total BMP10: Choose antibodies that recognize the mature domain of BMP10 (Asn317-Arg424 in humans) .

• For distinguishing prodomain-bound BMP10: Use an antibody specific to the prodomain (Ser20-Arg313) .

• For neutralization experiments: Select antibodies with demonstrated neutralizing activity in functional assays .

• For Western blot analysis: Consider whether you need antibodies that work under reducing or non-reducing conditions. Some BMP10 antibodies only work under non-reducing conditions .

• For immunohistochemistry: Verify that the antibody has been validated for IHC applications with appropriate positive controls .

Always validate antibody specificity using appropriate positive and negative controls in your experimental system.

What are the best methods to detect and quantify BMP10 in biological samples?

Several methodologies have been established for BMP10 detection and quantification:

• ELISA: Specific ELISAs have been developed to measure BMP10 levels in circulation. Studies have detected BMP10 at concentrations of 0.5-2 ng/mL in mouse serum and 1-3 ng/mL in human serum .

• Western blot analysis: For detecting BMP10 in cell lysates, researchers have used protocols including:

  • Sample preparation in RIPA buffer

  • SDS/PAGE (10%) separation

  • Immunoblotting with anti-BMP10 antibodies

  • Stripping and reprobing with controls (e.g., α-tubulin)

• Cell-based activity assays: Functional BMP10 can be detected through:

  • Alkaline phosphatase production in MC3T3-E1 mouse preosteoblast cells

  • SMAD6 induction in human umbilical vein endothelial cells (HUVECs)

  • ID1 or ID3 gene induction in C2C12 cells

How can I accurately quantify prodomain-bound BMP10 (pBMP10) in samples?

Quantification of pBMP10 requires careful methodology. Based on published protocols:

• Two-step quantification approach:

  • Initial quantification by Coomassie Blue staining on SDS-PAGE using BSA as a standard

  • Second round of quantification using immunoblotting with commercial BMP10 growth factor domain (GFD) as a standard

• Activity-based quantification:

  • Measure the biological activity of the sample using cell-based assays (SMAD phosphorylation or target gene induction)

  • Compare to activity curves generated with recombinant standards

• Immunoprecipitation followed by Western blot:

  • Immunoprecipitate BMP10 using 1 μg anti-human ALK1 antibody with 500 μg total protein

  • Detect using anti-BMP10 antibodies in Western blot analysis

Note that the concentration of pBMP10 is typically reported as the concentration of mature GFD in the pBMP10 complex .

How should I design a BMP10 neutralization experiment?

For effective neutralization experiments:

• Determine cell sensitivity: Different cell types have different sensitivities to BMP10. For example, 10 ng/mL BMP10 is typically used for C2C12 mouse myoblasts while 1 ng/mL is sufficient for endothelial cells .

• Antibody preparation: Pre-incubate BMP10 growth factor domain (GFD) with a 4-fold increased molar ratio of neutralizing antibody with 0.5% (v/v) BSA as a carrier protein. Incubate the mixture for 2 hours at room temperature before adding to cells .

• Readout selection: Choose appropriate readout systems:

  • Phosphorylation of SMAD1/5/8 (detectable after 30 minutes to 24 hours of stimulation)

  • Induction of ID1/ID3 or SMAD6 gene expression (typically 1 hour after treatment)

  • Alkaline phosphatase production in MC3T3-E1 cells

• Controls: Include:

  • Positive control (BMP10 alone)

  • Negative control (untreated cells)

  • Isotype control antibody

  • Specificity control (use related protein like BMP9 and specific antibody)

What considerations are important when studying BMP10 in cardiovascular disease models?

Key considerations include:

• Source of BMP10: Consider whether to use:

  • Recombinant human/mouse BMP10

  • Prodomain-bound BMP10 complex

  • Endogenous BMP10 from right atrium or circulation

• Disease context specificity:

  • For atrial fibrillation studies, repeated measurements of BMP10 (e.g., at baseline and after 2 months) provide better prognostic value than single measurements

  • For diabetic cardiomyopathy, consider BMP10's interactions with myocardial apoptosis, fibrosis, and immune response pathways

• Receptor complexes:

  • BMP10 signals through ALK1 in endothelial cells but may use different receptors in cardiac tissue

  • Consider the expression of BMPRII and ActRIIA as both are needed for complete BMP10 signaling

• Detection timeframe:

  • BMP10-induced Smad1/5/8 phosphorylation can last over 24 hours, significantly longer than many other signaling events

How do I distinguish between BMP10 and BMP9 activities in my experimental system?

BMP9 and BMP10 are structurally related and share signaling pathways, making differentiation challenging:

• Specific antibody neutralization:

  • Use specific neutralizing antibodies for BMP9 or BMP10

  • Test samples with anti-BMP9 alone, anti-BMP10 alone, and combination of both

  • Complete abolishment of activity only with both antibodies indicates the presence of both factors

• Receptor utilization analysis:

  • BMP9 and BMP10 both signal through ALK1, but with subtle differences in receptor complex formation

  • Silencing BMPRII and ActRIIA expressions completely abolishes BMP10 response

  • Overexpression of endoglin increases BMP9 response

• Gene expression fingerprinting:

  • Analyze specific downstream target genes that may be differentially regulated

  • For example, BMP10 treatment stimulates a panel of genes previously reported to be activated by the constitutively active form of ALK1

What explains contradictory findings regarding BMP10 activity in circulation?

The literature shows contradictory findings regarding circulating BMP10 activity, which can be explained by:

• Prodomain inhibition context-dependency:

  • The BMP10 prodomain inhibits BMP10 activity in C2C12 myoblast cells but not in multiple endothelial cell lines

  • These cell-type differences may explain contradictory findings in various assay systems

• Detection methodology variations:

  • Studies using ELISA detect BMP10 GFD protein in human and mouse sera

  • Some functional assays failed to detect circulating BMP10 activity in human serum

  • More recent studies identified BMP10 activity in mouse serum

• Sample preparation differences:

  • Native vs. denatured conditions affect detection

  • Presence of binding partners or inhibitors in different sample types

• BMP10 forms:

  • BMP10 can exist as cleaved mature dimer, uncleaved proform dimer, and uncleaved proform monomer

  • Different antibodies and assays may preferentially detect different forms

How can I study the role of BMP10 in cardiac development using antibody-based approaches?

Advanced approaches for studying BMP10 in cardiac development include:

• In situ hybridization combined with antibody staining:

  • In situ hybridization can detect BMP10 mRNA expression patterns

  • Follow with antibody staining to correlate mRNA with protein localization

  • This approach helps identify cells producing vs. responding to BMP10

• Conditional knockout models with antibody validation:

  • Use BMP10 antibodies to verify knockout efficiency in conditional animal models

  • Assess developmental phenotypes and compare to complete knockout (embryonic lethal) models

• Ex vivo heart culture systems:

  • Isolate embryonic hearts

  • Treat with neutralizing BMP10 antibodies at different developmental stages

  • Analyze effects on trabeculation and chamber formation

• Receptor-ligand interaction studies:

  • Use antibodies to block specific domains of BMP10

  • Analyze which interactions are essential for cardiac development

  • Correlate with known cardiac malformations in humans

Why might my BMP10 antibody show inconsistent results in different assay formats?

Several factors can contribute to inconsistent BMP10 antibody performance:

• Structural considerations:

  • BMP10 dimers may be disrupted under reducing conditions

  • Some antibodies (e.g., MAB2926) work only under non-reducing conditions

  • Epitope accessibility may differ between native and denatured proteins

• Prodomain effects:

  • The prodomain remains bound to mature BMP10 in many contexts

  • Antibodies targeting the mature domain may have variable access depending on prodomain conformation

• Post-translational modifications:

  • BMP10 can exist in cleaved and uncleaved forms

  • Different glycosylation patterns may affect antibody recognition

• Context-dependent activity:

  • BMP10 activity is cell-type specific (e.g., different in C2C12 vs. endothelial cells)

  • Expression levels of co-receptors like endoglin affect signaling strength

What are the best experimental controls when using BMP10 antibodies?

Rigorous controls are essential for BMP10 antibody experiments:

• Specificity controls:

  • Test antibody against recombinant BMP10 and related family members (especially BMP9)

  • Include samples from BMP10 knockout models when available

  • Use siRNA knockdown of BMP10 in cell systems

• Technical controls:

  • Include isotype-matched control antibodies

  • For neutralization assays, include heat-inactivated antibody

  • For immunoprecipitation, include control IgG pull-downs

• Detection system controls:

  • For Western blots, include loading controls (e.g., α-tubulin)

  • For qPCR, use validated reference genes like β-2-microglobulin

  • For functional assays, include dose-response curves with recombinant standards

• Biological validation:

  • Confirm key findings with multiple antibodies targeting different epitopes

  • Validate protein detection with mRNA expression data

  • Cross-validate with functional assays (e.g., reporter gene activation, SMAD phosphorylation)

How can BMP10 antibodies be used to study therapeutic potential in cardiovascular diseases?

BMP10 antibodies offer several approaches for exploring therapeutic applications:

• Biomarker validation studies:

  • Recent research shows that repeated measurement of BMP10 after 2 months significantly strengthens associations with risk of ischemic stroke and heart failure in AF patients

  • Antibody-based assays could help identify patients who would benefit from intensified monitoring or treatment

• Therapeutic targeting assessment:

  • Neutralizing antibodies can help determine if BMP10 inhibition would be beneficial in conditions like:

    • Pulmonary arterial hypertension (PAH)

    • Diabetic cardiomyopathy

    • Hereditary hemorrhagic telangiectasia

• Receptor-specificity studies:

  • Domain-specific antibodies can help determine which BMP10 interactions should be targeted

  • Crystal structure studies of BMPRII extracellular domain in binary and ternary receptor complexes with BMP10 provide insights for targeted approaches

• Prodomain-based therapeutics:

  • If the prodomain inhibits BMP10 activity in certain contexts, prodomain-derived peptides might have therapeutic potential

  • Antibodies can help validate such approaches in preclinical models

What new methodologies are emerging for studying BMP10 signaling dynamics?

Emerging approaches include:

• Live-cell imaging with reporter systems:

  • Combine BMP10 antibody-based detection with real-time imaging of SMAD translocation

  • Monitor signaling dynamics over time in different cell types

• Mass spectrometry-based interactome analysis:

  • Use antibodies to pull down BMP10 complexes

  • Identify novel interaction partners in different cardiovascular cell types

  • Map context-specific signaling networks

• Single-cell analysis:

  • Combine antibody-based detection with single-cell transcriptomics

  • Identify cell populations responding to BMP10 in heterogeneous tissues

  • Map signaling output at single-cell resolution

• In vivo imaging:

  • Develop antibody-based probes for non-invasive imaging of BMP10 activity

  • Monitor disease progression and therapeutic response in cardiovascular disease models